Abstract
Efficacy, Drug Safety and Serum Inflammatory Factors of Secukinumab in the Treatment of Plaque Psoriasis
Department of Dermatology, Tonglu First People’s Hospital, Hangzhou, Zhejiang 311500, 1Department of Dermatology, Hangzhou First People’s Hospital, Hangzhou, Zhejiang 310006, China
Correspondence Address:
Jia Li Xu, Department of Dermatology, Tonglu First People’s Hospital, Hangzhou, Zhejiang 311500, China, E-mail: xu96168@163.com
Our main objective is to study the efficacy, safety and influence on inflammatory factors of secukinumab in the treatment of plaque psoriasis. A total of 120 patients admitted to Tonglu People’s Hospital from December 2021 to November 2022 were selected as the objects of this drug comparison and were divided into the observation group and the control group. The drugs used in the study were secukinumab and compound clobetasol propionate ointment. The treatment lasted for 4 w. The drug effects of the two groups were compared, including the total effective rate, adverse reactions, anti-inflammatory situation, etc. After treatment, the total effective rates of the observation group and the control group were 96.67 % and 86.67 %, respectively (p<0.05). The rates of adverse drug reactions were 1.67 % and 3.33 %, respectively (p>0.05). The anti-inflammatory effect of the observation group was better (p<0.05) than the control group. Secukinumab has good drug efficacy, high safety and good anti-inflammatory effect, which is worthy of clinical recommendation.
